On February 21, 2024, Dyadic International Inc. (NASDAQ: DYAI) garnered significant attention from investors as its stock surged by 19.2%, marking the highest volume in the past six months. The company, a global technology firm specializing in advanced microbial platforms for bio-production and protein development to meet clinical demands, came into focus. This morning, news broke that Dyadic had extended its partnership with the Israel Institute for Biological Research (IIBR) and Life Sciences Research Israel (LSRI), its commercial affiliate, to focus on developing solutions for emerging diseases.
The partnership aims to harness the company's expertise in flexible-scale protein bio-production using microbial platforms. Moreover, it will capitalize on IIBR's ability to identify antigens and antibodies for manufacturing solutions to emerging diseases and threats. In a broader context, this collaboration seeks to advance the development of effective vaccines and treatments to address global health challenges, with the goal of commercialization in mind. Commercialization of these discoveries will be facilitated through licensing agreements.
IIBR is set to contribute to the enhancement of Dyadic International's C1 cell lines by utilizing proprietary gene sequences. This collaboration aims to improve the bio-manufacturing of neutralizing agents and recombinant vaccines. The focus of the partnership will be on addressing emerging diseases through various global out-licensing initiatives aimed at broadening access.
These actions would additionally enhance the accessibility of vaccines and antibodies for patients. LSRI has previously partnered with Dyadic International, with the collaboration beginning in January 2018 and later expanding during the pandemic. LSRI has expressed satisfaction with the progress made through the utilization of Dyadic International's C1 technology for the co-development of vaccines.
Dyadic International Inc. (NASDAQ: DYAI) is showing several bullish signs, having risen for three consecutive days. Additionally, the MACD (Moving Average Convergence Divergence), a momentum indicator, has turned upward, signaling a bullish crossover with the EMA (Exponential Moving Average). Both the EMA and MACD track the relationship between two moving averages of a security's price, indicating that the stock has entered an upward trend. This positions DYAI as one to keep a close eye on in the near term.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
